NCT07585071
IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia
StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
See at-risk trials from Institute of Hematology & Blood Diseases Hospital, China
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Dec 31, 2026 to Dec 31, 2027
- Start date: Jun 15, 2026 to Dec 15, 2026
- Eligibility criteria expanded, about 41 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence and severity of adverse events
Timeframe: Up to 3 months after IASO206 infusion
Secondary (1)
Proportion of patients achieving response
Arms and interventions
IASO206Experimental
Subjects will receive a single infusion of IASO206 injection in a 3+3 dose-escalation design. Three ascending dose cohorts are planned: 1E8 TU, 3E8 TU, and 5E8 TU. In each dose cohort, the first subject will be observed for at least 3 weeks after infusion before subsequent subjects in the same cohort receive IASO206 injection.
Biologicals: IASO206 injection